Topic: How a shared-risked partnership model can improve the success rates of getting to IND and beyond? Dr. Dale Dhanoa is a visionary executive with significant experience in pharma/biotech industry in directing and managing all aspects of R&D, drug design, discovery and drug development, capital raise and strategic partnering between biotech and pharmaceutical companies. He has over 20 years of broad and in-depth experience from a major pharmaceutical company Merck & Co. Inc., and several biotech companies including Predix Pharmaceuticals (M/A with Epix Pharma), 3-Dimensional Pharmaceuticals (acquired by J&J), Alanex Corp (acquired by Agouron/Warner Lambert/Pfizer), Synaptic Pharmaceuticals Corporation (Nasdaq:snap; acquired by H. Lundbeck A/S), PharmaCore acquired by Cambrex) and Akaal Pharma. As the CEO of Akaal Pharma (Australia and USA), a Phase 2 clinical drug was out-licensed to a biopharma in 2018. An Alzheimer’s drug designed by Dr. Dhanoa at Predix Pharmaceuticals was out-licensed to GlaxoSmithKline for $1.2 Billion. An autoimmune drug candidate was partnered with Amgen.